<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417154</url>
  </required_header>
  <id_info>
    <org_study_id>2017LS116</org_study_id>
    <secondary_id>HM2017-33</secondary_id>
    <nct_id>NCT03417154</nct_id>
  </id_info>
  <brief_title>Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS</brief_title>
  <official_title>Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in&#xD;
      combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk&#xD;
      myelodysplastic syndrome (MDS) who are not eligible for or decline hematopoietic stem cell&#xD;
      transplant. It includes a randomized pilot sub-study during stage 1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Treatment ineffective&#xD;
  </why_stopped>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: Dosing Schedule of low-dose Cyclophosphamide</measure>
    <time_frame>4 weeks from start of treatment</time_frame>
    <description>Incidence of adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Clinical benefit and immunologic response of the combination therapy</measure>
    <time_frame>90 days from start of treatment</time_frame>
    <description>Overall response rate at 90 days from treatment start. Response is defined as CR&#xD;
+ CRi + CRp + PR in AML and CR/PR/hematologic improvement (HI) in MDS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>30 days from start of treatment</time_frame>
    <description>Incidence of overall response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>6 months from start of treatment</time_frame>
    <description>Incidence of progression free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>6 months from start of treatment</time_frame>
    <description>Incidence of overall survival.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Higher Risk Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Stage 1 Arms 1&amp;2: Nivolumab and Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Nivolumab and Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.</description>
    <arm_group_label>Stage 1 Arms 1&amp;2: Nivolumab and Cyclophosphamide</arm_group_label>
    <arm_group_label>Stage 2: Nivolumab and Cyclophosphamide</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 1 Arm 1: Low dose Cyclophosphamide (CTX)</intervention_name>
    <description>Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment</description>
    <arm_group_label>Stage 1 Arms 1&amp;2: Nivolumab and Cyclophosphamide</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 1 Arm 2: Low dose Cyclophosphamide (CTX)</intervention_name>
    <description>Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment</description>
    <arm_group_label>Stage 1 Arms 1&amp;2: Nivolumab and Cyclophosphamide</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 2: Low dose Cyclophosphamide (CTX)</intervention_name>
    <description>Stage 2: Oral cyclophosphamide as assigned for up to 4 treatment courses with each treatment course equal to 28 days.</description>
    <arm_group_label>Stage 2: Nivolumab and Cyclophosphamide</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Meets one of the following disease criteria:&#xD;
&#xD;
               -  Primary (de novo) AML or higher-risk MDS with induction failure: No CR after 2 or&#xD;
                  more induction attempts with high dose chemotherapy or hypomethylating agents or&#xD;
                  other agents; no CR after 1 induction attempt and not eligible for a 2nd&#xD;
                  induction.. Higher risk MDS defined as risk score &gt; 4.5 based on the revised IPSS&#xD;
                  criteria.&#xD;
&#xD;
               -  Secondary AML (from antecedent hematologic malignancy or treatment-related): Not&#xD;
                  in CR after 1 or more cycles of chemotherapy.&#xD;
&#xD;
               -  Relapsed AML: Blasts ≥5% in bone marrow or peripheral blood after prior&#xD;
                  attainment of CR; relapse at any time but currently ≥100 days following&#xD;
                  allogeneic HCT.&#xD;
&#xD;
               -  Relapsed MDS: Morphologic evidence of relapse or increase in blasts ≥5% in bone&#xD;
                  marrow or peripheral blood after prior attainment of hematologic improvement; or&#xD;
                  partial or complete response ; relapse at any time but currently ≥100 days&#xD;
                  following allogeneic HCT..&#xD;
&#xD;
          -  ECOG Performance Status ≤ 2 - refer to Appendix II&#xD;
&#xD;
          -  Adequate organ function within 14 days of study registration defined as:&#xD;
&#xD;
               -  Absolute Lymphocyte Count: ≥ 500 cells/mm3&#xD;
&#xD;
               -  Hepatic: total bilirubin ≤ 3 x upper limit of institutional normal (ULN); ALT and&#xD;
                  AST ≤ 5 x ULN&#xD;
&#xD;
               -  Renal: Serum creatinine ≤ 2 mg/dL&#xD;
&#xD;
               -  Pulmonary: No oxygen requirement on room air or requiring ≤ 2L supplemental O2&#xD;
&#xD;
          -  Sexually active females of child bearing potential and males with partners of child&#xD;
             bearing potential must agree to use effective contraception during therapy and&#xD;
             continuing (23 weeks for females, 31 weeks for males) after the last dose of nivolumab&#xD;
&#xD;
          -  Voluntary written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding -The agents used in this study fall under Pregnancy Category&#xD;
             D - Drugs which have caused, are suspected to have caused or may be expected to cause,&#xD;
             an increased incidence of human fetal malformations or irreversible damage. Women of&#xD;
             childbearing potential must have a negative pregnancy test (urine or serum) within 7&#xD;
             days of study drug administration.&#xD;
&#xD;
          -  Prior allogeneic hematopoietic stem cell transplantation within previous 100 days&#xD;
             (note patients with a prior alloHSCT receive nivolumab at the reduced dose of 1 mg/kg)&#xD;
&#xD;
          -  Signs or symptoms of active graft versus host disease&#xD;
&#xD;
          -  Active pneumonitis or uncontrolled infection&#xD;
&#xD;
          -  Received chemotherapy drugs within previous 2 weeks&#xD;
&#xD;
          -  Estimated life expectancy &lt;28 days in the opinion of the enrolling investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fiona He, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology, Oncology and Transplantation, Masonic Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

